Avion launches precision treatment for Parkinson’s disease

Avion Pharmaceuticals introduced its Parkinson’s disease treatment, Dhivy, the first carbidopa/levodopa fractional tablet intended to be divided, according to a press release.

The FDA approved Dhivy in November 2021. According to the release, the design allows for increased precision when dosing medication, with the fractional tablet scored into four segments containing 6.25/25 mg of carbidopa/levodopa (CD/LD).

In a recent update to treatment guidelines for early PD, the American Academy of Neurology recommended patients initiate with the lowest effective dose of immediate-release CD/LD.

“While no two patients with Parkinson's disease are the same, the burden all patients face is significant,” Harold “Art” Deas, CEO of Alora Pharmaceuticals, Avion’s parent company, said in the release. “Avion is pleased to bring Dhivy to the market to help these patients and their providers better manage CD/LD dosing needs with a more individualized experience. The innovative tablet design provides a new way to individualize every dose and mitigate some of the challenges patients currently face when it comes to their medication management.”